Table 2.
Sample clinical characteristics of XLH adults aged 26 and over (N= 30)
Mean | Range | |
---|---|---|
Age at diagnosis | 9 | 0–47 |
N | |
---|---|
XLH severity (self-reported) | |
Mild | 7 |
Moderate | 10 |
Severe | 9 |
Don't know | 4 |
Current treatments | |
None | 5 |
Phosphate | 22 |
Calcitriol/Vitamin D | 24 |
Dental procedures | 7 |
Surgery | 6 |
Physiotherapy | 13 |
Analgesicsa | 22 |
Other treatments | 9 |
Past treatments | |
Phosphate | 28 |
Calcitriol/Vitamin D | 29 |
Dental procedures | 27 |
Surgery | 22 |
Physiotherapy | 21 |
Growth hormone | 2 |
Analgesicsa | 2 |
Other treatments | 5 |
Family history (mother or father) | |
Yes | 16 |
Nob | 14 |
Co-morbidities | |
None | 17 |
Musculoskeletal co-morbidities | 7 |
Other co-morbidities | 8 |
aNot a prompted response option on the background questionnaire
bReasons included having a parent with no confirmed diagnosis of XLH, being adopted and having a spontaneous gene mutation